- Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
- Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
- Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results
- Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024
- Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal
- Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit
- Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Altamira Therapeutics Provides Investor and Business Update
- Altamira Therapeutics to Host Investor & Business Update Call on December 11th
More ▼
Key statistics
On Friday, Altamira Therapeutics Ltd (CYTO:NAQ) closed at 1.64, 21.48% above the 52 week low of 1.35 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.65 |
---|---|
High | 1.66 |
Low | 1.60 |
Bid | 1.57 |
Offer | 1.58 |
Previous close | 1.62 |
Average volume | 400.35k |
---|---|
Shares outstanding | 2.24m |
Free float | 2.22m |
P/E (TTM) | -- |
Market cap | 3.67m USD |
EPS (TTM) | -16.35 USD |
Data delayed at least 15 minutes, as of May 03 2024 20:59 BST.
More ▼